Trastuzumab for HER2-positive metastatic breast cancer: Clinical and economic considerations

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 179-187

  Jeyakumar, Alwin ^a   Younis, Tallal ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Breast cancer; Clinical trials; Cost effectiveness analysis; Economics; HER2 positive; Palliative; Trastuzumab

Indexed keywords

ANASTROZOLE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEART DISEASE; HEART FAILURE; HUMAN; HYPOKALEMIA; INJECTION SITE REACTION; LOADING DRUG DOSE; LUNG TOXICITY; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA;

EID: 84859727619     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6460     Document Type: Review

References (48)

1. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55-62.
2. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutionalbased review. J Clin Oncol. 2010;28(1):92-98.
3. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. Jun 2007;18(6):977-984.
4. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6(3):240-246.
5. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology Guidance Statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868-3874.
6. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbBrelated gene in a human mammary carcinoma. Science. Sep 6, 1985; 229(4717):974-976.
7. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A. 1999;96: 4995-5000.
8. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996;15:254-264.
9. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523-1530.
10. Giatromanolaki A, Koukourakis MI, Simopoulos C, et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res. 2004;10:7972-7977.
11. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989;4:362-366.
12. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. Apr 2000; 6(4):443-446.
13. Morse MA, Hobeika A, Osada T, et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med. Sep 6, 2007;5:42.
14. Product Monograph Herceptin: Distributed By: Hoffmann-La Roche Limited, 2455 Meadowpine Boulevard, Mississauga, Ontario, L5N 6L7. Jan 6, 2012:1-75.
15. Vogel CL, Cobleigh MA, Tripathy D, et al. First-line herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):37-42, Review.
16. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
17. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265-4274.
18. Gasparini G, Gion M, Mariani L, et al. Randomized Phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat. 2007;101:355e65.
19. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA Study. J Clin Oncol. 2011;29(3):264-271.
20. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24(18):2786-2792.
21. Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:976e83.
22. Bontenbal M, Seynaeve C, Stouthard J, et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/ docetaxel as firstline chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study). J Clin Oncol. 2008;26:1014.
23. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-2730.
24. O'Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004;5(2):142-147.
25. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529-5537.
26. Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer-Results of the eLEcTRA trial. Breast. Aug 19, 2011.
27. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol. 2009;27(12):1999-2006.
28. Von Minckwitz G, Schwedler K, Schmidt M, et al. On behalf of the GBG 26/ BIG 03-5 study group and participating investigators: Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. Jul 7 2011:2273-2281.
29. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-1130.
30. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med. 2012;366(2):109-119.
31. Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398-405.
32. Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. Curr Oncol. Jun 2008;15(3):136-142.
33. Younis T, Skedgel C. Is trastuzumab a cost-effective treatment for breast cancer? Expert Rev Pharmacoecon Outcomes Res. Oct 2008;8(5):433-442.
34. United Kingdom: National Institute for Health and Clinical Excellence (NICE). Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA 34 Guidance). Available at: http://www.nice.org.uk/nicemedia/pdf/advancedbreastcancerno34PDF.pdf (Accessed last January 20, 2012).
35. Neyt MJ, Albrecht JA, Clarysse B, Cocquyt VF. Cost-effectiveness of herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care. Winter 2005;21(1):132-137.
36. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol. Jun 2005;16(6):909-914.
37. Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody antihuman epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Clin Oncol (R Coll Radiol). Mar 2007;19(2):162-163.
38. Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol. Aug 2008;31(4):363-368.
39. Perez-Ellis C, Goncalves A, Jacquemier J, et al. Cost-effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer. Am J Clin Oncol. July 18, 2009.
40. Fleeman N, Bagust A, Boland A, et al. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assess. 2011;15(42):1-93, iii-iv.
41. Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol. Nov 2010;21(11):2161-2168.
42. Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin. Jul-Aug 2008;58(4):231-244.
43. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. Apr 2000; 9(3):235-251.
44. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. Jul-Sep 2000;20(3):332-342.
45. Mason H, Baker R, Donaldson C. Willingness to pay for a QALY: past, present and future. Expert Rev Pharmacoecon Outcomes Res. Dec 2008;8(6):575-582.
46. Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer. Feb 1, 2009;115(3):489-498.
47. Delea TE, Tappenden P, Sofrygin O, et al. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. Eur J Health Econ. Jun 24, 2011.
48. Younis T, Rayson D, Sellon M, Snow S, Skedgel C. The economics of second line therapy with trastuzumab plus capecitabine or lapatinib plus capecitabine for Her2/neu positive metastatic breast cancer: flip a coin? Poster Presentation at the American Society of Clinical Oncology' 2009 Breast Cancer Symposium: San Francisco, CA. Oct 2009 (Abstract No 163).